Why the dance between manufacturers and PBMs continues
States have targeted co-pay accumulators, claiming they run up costs for patients who need expensive specialty drugs. Here’s why their legislation hasn’t yet had the intended impact.
Policy
Dive into the FDA ban on flavored e-cigarettes
Beginning Feb. 1, the e-cigarette industry will look much different.
Questions linger after Hahn takes over as FDA commissioner
Some Senators who questioned Hahn during his confirmation hearing expressed concern about his lack of regulatory and public policy experience.
Infographic: What could you buy with the $20.5 trillion Elizabeth Warren’s health plan calls for in new federal spending?
That number got many of us at MM&M thinking: What else can be bought with $20,500,000,000,000?
It’s back! Bill requiring list prices in DTC ads resurfaces
Sens. Chuck Grassley and Dick Durbin hoped to pass the bill through unanimous consent last week, ahead of impeachment proceedings and a budget battle.
FDA’s first ‘modified risk’ tobacco products set precedent
They could set the standard for vaping products.
Rare disease agency organizes to help patient advocate facing deportation
Cambridge BioMarketing organized an awareness campaign to support patient advocate Maria Isabel Buseo, who came to the U.S. 16 years ago for a clinical trial.
Drugmakers want in on Purdue’s bankruptcy settlement to end opioid lawsuits
J&J, Teva, Endo, Allergan and Mallinckrodt have a plan to contribute to the trust created by Purdue’s bankruptcy settlement.
CDC official stresses urgency of investigating vaping to Congress
The CDC’s principal deputy director said “hundreds” of new lung illness cases have been reported since last week.
What 5 states have done on vaping in one week
In the week since the Trump administration proposed banning flavored e-cigarettes, five states have taken action of their own.
